Ventus Therapeutics selects potential first|in|class cGAS inhibitor as ...

Ventus Therapeutics Nominates Potential First-in-Class cGAS ...

“cGAS is a highly coveted target for pro-inflammatory and neurodegenerative diseases for which no inhibitor has advanced into clinical ...

Ventus Therapeutics Announces Successful Completion of Phase 1 ...

Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor.

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in ...

D. “We are eager to advance this therapeutic candidate and bring the potential of cGAS inhibition to patients suffering from inflammatory ...

Ventus Therapeutics Announces Successful Completion of Phase 1 ...

Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor.

VENT-03, a First-in-Class cGAS Inhibitor - Ventus Therapeutics

The virtual event will feature VENT-03, a first-in-class cGAS inhibitor in development for lupus and other inflammatory disorders.

Ventus Therapeutics selects potential first-in-class cGAS inhibitor as ...

Ventus Therapeutics Inc. has nominated a potential first-in-class cyclic GMP-AMP synthase (cGAS) inhibitor, VENT-03, as the company's first ...

Ventus Therapeutics Provides Updates on cGAS Inhibitor Program ...

Ventus' first target screen was conducted in 2020, which led to the nomination of three development candidates in 2022, including: VENT-03, a ...

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in ...

D. "We are eager to advance this therapeutic candidate and bring the potential of cGAS inhibition to patients suffering from inflammatory ...

Ventus Therapeutics Nominates Potential First-in-Class cGAS ... - Gale

cGAS is a highly coveted target for pro-inflammatory and neurodegenerative diseases for which no inhibitor has advanced into clinical development to date, ...

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in ...

D. 'We are eager to advance this therapeutic candidate and bring the potential of cGAS inhibition to patients suffering from inflammatory disorders with ...

VENT-03 - BioWorld

Ventus Therapeutics Inc. has nominated a potential first-in-class cyclic GMP-AMP synthase (cGAS) inhibitor, VENT-03, as the company's first ...

Ventus Therapeutics Announces Results from Phase 1 Clinical Trial ...

Ventus Therapeutics today announced results from its Phase 1 clinical trial of VENT-02, a novel, oral, brain-penetrant NLRP3 inhibitor.

Ventus Therapeutics Announces First Participant Dosed in Clinical ...

In addition, Ventus has out-licensed VENT-01, a peripherally-restricted NLRP3 inhibitor, to Novo Nordisk A/S. These programs exemplify Ventus' ...

cGAS - Ventus Therapeutics

Aberrant activation of the cGAS pathway is implicated in a wide range of diseases · Validation of the cGAS pathway · ReSOLVE™ in action · VENT-03: A first-in-class ...

Ventus Therapeutics - Recent News & Activity - Crunchbase

Business Wire — Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively ... ... cGAS, taking ...

Ventus Therapeutics Closes $100 Million Series B Financing

Based on these breakthroughs, Ventus identified and optimized novel and differentiated NLRP3 inhibitors, including high potency and quality ...

Ventus Therapeutics - Recent News & Activity - Crunchbase

Business Wire — Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively ... ... cGAS, taking option ...

Ventus' NLRP3 Inhibitor Shows Potential for CNS Diseases in ...

Ventus Therapeutics, a US-based clinical-stage biopharmaceutical company leveraging its exclusive structural biology and computational ...

WO2019153002A1 - 2,3,4,5-tetrahydro-1h-pyrido[4, 3-b]indole ...

... potential cGAS inhibitor [An et ah, ./. Immunol. 194, 4089-4093 (2015)] ... Ventus Therapeutics U.S., Inc. PYRIDO[4,3-b]INDOLE DERIVATIVES AND THEIR USE ...

Kayothera selects retinoid pathway inhibitor as development ...

has selected KAYO-1609, an oral retinoid pathway inhibitor, as its first ... Ventus Therapeutics selects potential first-in-class cGAS inhibitor ...